Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Johns Hopkins Medical Institutes
Validation of serum biomarkers can help determine broader use of candidate markers
February 5th, 2006
Independent validation of serum biomarkers can help determine the broader use of candidate markers. Scientists in the United States report, "We previously selected a panel of 3 breast cancer biomarkers (BC1, BC2, and BC3) from serum samples collected at a single hospital based on their collective contribution to the optimal separation of breast cancer patients and noncancer controls by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The identities and general applicability of these markers, however, were unknown." "In this study," wrote J.N. Li and colleagues, "we performed protein expression profiling on...
Source: Women's Health Law Weekly (2006-02-05)
|
